AstraZeneca PLC

AZN: XLON (GBR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|f^>rLOCK|z!jLOCK|tKQ$?^c

AstraZeneca Earnings: First-Quarter Results Consistent With 2025 Full-Year Guidance

AstraZeneca posted 7% reported year-on-year revenue growth, which includes a 3% currency headwind, and core operating profit growth of 12%. Management reiterated its full-year guidance of high-single-digit revenue growth and low-double-digit core earnings per share growth.

Sponsor Center